Time‐course manganese chloride biodistribution and manganese‐induced MRI contrast in mouse organs
Magnetic Resonance in Medicine · 2025
DOI: 10.1002/mrm.30522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance in Medicine, 2025. Verfasst von Keyu Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Contrast Media, Manganese Compounds, Chlorides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: New Frontiers in Research Fund, Dean's Spark Professorship, Canada Foundation for Innovation.
Abstract (Originalsprache)
Purpose
To optimize manganese‐enhanced MRI (MEMRI) in mice by profiling the time‐course biodistribution and associated T 1 contrast enhancement of MnCl 2 injected subcutaneously to avoid abrupt spikes in blood manganese levels.
Methods
Manganese (Mn) biodistribution and Mn‐induced T 1 contrast in healthy female adult CD‐1 mice were investigated at two doses (0.2 and 0.4 mmol/kg) and 2, 6, and 24 h following injection. T 1 ‐weighted MRI and T 1 mapping were performed at 3 T. The heart, liver, kidneys, leg skeletal muscle, lungs, spleen, and blood were collected and quantified for Mn content using inductively coupled plasma atomic emission spectroscopy. Toxicity was assessed on hematoxylin and eosin histological sections of the heart, liver, kidneys, lungs, and spleen.
Results
An injection dose of 0.2 mmol/kg produced significant T 1 enhancement in the heart, liver, and kidneys, reaching peak enhancement at 2 h following injection. Doubling the dose did not produce further T 1 enhancement in the heart, liver, nor kidneys. Skeletal muscle reached peak enhancement at 24 h and required an injection dose of 0.4 mmol/kg. Inductively coupled plasma atomic emission spectroscopy–measured tissue‐level Mn content corroborated MRI results and revealed peak Mn concentration also at 2 h following injection in the spleen, lungs, and blood. No organ toxicity was observed at either dose on histology.
Conclusion
The subcutaneous injection route provided substantial T 1 contrast enhancement in all tissues investigated, without toxicity at the maximum dose of 0.4 mmol/kg tested. However, the injection dose and optimal postinjection imaging interval must be tailored to the organ of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
- Translational Biology & Engineering Program, Ted Rogers Centre for Heart Research, Toronto, Ontario, Canada.
- Shanghai InnoStar Bio-tech Co., Ltd., Shanghai, China.
- China State Institute of Pharmaceutical Industry, Shanghai, China.
- The Edward S. Rogers Sr. Department of Electrical and Computer Engineering, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Keyu Zhuang, Hai-Ling Margaret Cheng
Förderung
- New Frontiers in Research Fund
- Dean's Spark Professorship
- Canada Foundation for Innovation
- Natural Sciences and Engineering Research Council of Canada
- Canadian First Research Excellence Fund
Zitieren
APA
Zhuang, K., Vollett, K. D. W., Hou, M., Chang, Y., & Cheng, H. M. (2025). Time‐course manganese chloride biodistribution and manganese‐induced MRI contrast in mouse organs. Magnetic Resonance in Medicine. https://doi.org/10.1002/mrm.30522
Vancouver
Zhuang K, Vollett KDW, Hou M, Chang Y, Cheng HM. Time‐course manganese chloride biodistribution and manganese‐induced MRI contrast in mouse organs. Magnetic Resonance in Medicine. 2025. doi:10.1002/mrm.30522
BibTeX
@article{Zhuang2025,
author = {Zhuang, Keyu and Vollett, Kyle D W and Hou, Minbo and Chang, Yan and Cheng, Hai-Ling Margaret},
title = {Time‐course manganese chloride biodistribution and manganese‐induced MRI contrast in mouse organs},
journal = {Magnetic Resonance in Medicine},
year = {2025},
doi = {10.1002/mrm.30522}
}
EUVIMED